Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active:	No
Cancer Type:	Neuroblastoma Sarcoma	NCT ID:	NCT03709680
Trial Phases:	Phase I Phase II	Protocol IDs:	A5481092 (primary) NCI-2019-02215
Eligibility:	2 - 20 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Pfizer Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT03709680

Summary

A study to learn about safety and find out maximum tolerable dose of palbociclib given in
combination with chemotherapy (temozolomide with irinotecan or topotecan with
cyclophosphamide) in children, adolescents and young adults with recurrent or refractory
solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor
activity of palbociclib in combination with topotecan and cyclophosphamide in children,
adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn
about the efficacy of palbociclib in combination with irinotecan and temozolomide when
compared with irinotecan and temozolomide alone in the treatment of children, adolescents,
and young adults with recurrent or refractory Ewing sarcoma (EWS).

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.